Novel monoclonal antibody could help revolutionize treatment of children with
October 16, 2021
Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children’s Research Hospital clinical trial that included a novel monoclonal antibody produced onsite. The findings appeared today in the Journal of Clinical Oncology. Neuroblastoma is a cancer of immature nerve cells in the sympathetic nervous …